Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

497 - Droplet digital PCR measurement of c-Met gene amplification in plasma cell free DNA in patients with advanced NSCLC

Date

17 Dec 2016

Session

Poster lunch

Presenters

Hong-Fei Gao

Citation

Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574

Authors

H. Gao, X. Zhang, J. Yang, Y. Wu

Author affiliations

  • Lung Cancer, Guangdong General Hospital, 510080 - Guangzhou/CN
More

Resources

Abstract 497

Background

Advanced NSCLC patients with c-Met amplification can respond to c-Met inhibitors. Unfortunately, the lack of adequate tissue often precludes c-Met testing. We hypothesized that plasma cell-free DNA (cfDNA) can offer an alternative source of biologic material for testing.

Methods

We designed a target region on exon 4 of c-Met gene, used RNaseP as the reference gene. We evaluated this c-Met:RNaseP ddPCR assay to determinate c-Met amplification in plasma cfDNA in 34 patients with advanced NSCLC who received c-Met inhibitor therapy, results were correlated with clinical findings.

Results

The concordance rate of ddPCR with FISH was not high (55.9%); however, patients who were c-Met-positive by ddPCR had significantly longer PFS after c-Met inhibitor therapy compared with c-Met-negative patients (4.352 months and 1.657 months, respectively, P = 0.008).

Conclusions

Our results demonstrated that this ddPCR method can be used to evaluate c-Met status in plasma cfDNA samples. The c-Met status determined in cfDNA may have potential as a predictive factor for PFS after c-Met inhibitor therapy.

Clinical trial indentification

not a clinical trial

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings